摩根士丹利最新研报维持英普乐医疗系统(INSP)"超配"评级,显示该机构持续看好这家专注睡眠呼吸治疗领域的医疗器械公司发展前景。
这份发布于15日的评级报告,正值医疗科技板块经历阶段性调整之际。分析师指出,英普乐创新的植入式神经刺激疗法在阻塞性睡眠呼吸暂停治疗领域仍具独特优势,其商业化进程及医保覆盖范围的拓展将成为未来关键增长驱动力。
当前市场密切关注该公司即将发布的季度财报,特别是其核心产品Inspire上呼吸道刺激系统的临床采用率及产能扩张计划。行业观察人士认为,随着全球睡眠健康管理需求持续攀升,该公司的技术壁垒可能带来差异化竞争优势。
(完) 北京时间15日21:18
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.